Clinical trials: Non-Hodgkin Lymphoma, B-cell
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
This is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of ABT-199 under a once daily dosing schedule.
- Trial name
- NCT01328626
- Testing
- ABT-199
- Where
- 10 sites in United States, Australia
- Volunteers
- 222 people
- Sponsor
- AbbVie
Refractory Diffuse Large B Cell Lymphoma
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete…
- Trial name
- ZUMA-6 (NCT02926833)
- Testing
- KTE-C19, Atezolizumab, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Kite, A Gilead Company
Advanced Cancer, Solid Tumor, Adult
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas.
- Conditions
- Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
- Trial name
- NCT03922204
- Testing
- MCLA-145, Pembrolizumab (Keytruda)
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Merus B.V.
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT03299738
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai AbelZeta Ltd.
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.
Lymphoma, Large-Cell, Diffuse
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584.
- Trial name
- NCT00511043
- Testing
- PTK787
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- David Rizzieri, MD
Diffuse Large B-cell Lymphoma
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL
This retrospective study aimed to investigate the combined prognostic values of intratumoral metabolic heterogeneity (MH), disseminate feature (Dmax) and total metabolic tumor volume (TMTV) by 2-deoxy-2-[18F]fluoro-D-glucose…
- Trial name
- NCT05113576
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
The objective of this study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies.
- Trial name
- NCT07106749
- Testing
- CD180 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Diffuse, Large B-Cell, Lymphoma
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a…
- Trial name
- NCT02391116
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 32 sites in Australia, Belgium and 8 more
- Volunteers
- 67 people
- Sponsor
- Bayer
Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready…
- Conditions
- Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
- Trial name
- QUADvance (NCT07284433)
- Testing
- Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T
- Where
- 13 sites in United States, Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Diffuse Large B-Cell Lymphoma
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of…
- Trial name
- NCT07059650
- Testing
- DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Dizal Pharmaceuticals
Diffuse Large B Cell Lymphoma (DLBCL)
Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order to allow a better…
- Trial name
- CHARTHER (NCT07181785)
- Testing
- Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy
- Where
- Italy
- Volunteers
- 555 people
- Sponsor
- Andrés José Maria Ferreri
Diffuse Large B-Cell Lymphoma
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
- Trial name
- NCT06665217
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
B-cell Acute Lymphoblastic Leukemia
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human CD19 targeted DASH CAR-T Cells injection, and to preliminarily…
- Trial name
- NCT05651191
- Testing
- Human CD19 Targeted DASH CAR-T Cells Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or older.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Low-Grade
- Trial name
- NCT01263418
- Testing
- Ofatumumab
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease
Host Dendritic Cells in Allograft Patients
The purpose of this study is to assess preliminary efficacy and to determine the safety and feasibility of ex vivo generated dendritic cell (HDC) infusion with and without donor lymphocyte infusion (DLI) after allogeneic stem…
- Conditions
- Relapsed Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Lymphoma
- Trial name
- NCT00935597
- Testing
- MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
B Cell Lymphomas, Multiple Myeloma
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use…
- Conditions
- B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression
- Trial name
- NCT02840110
- Testing
- ACTR T Cell Product
- Where
- 16 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cogent Biosciences, Inc.
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
- Trial name
- NCT07121946
- Testing
- LTZ-301
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- LTZ Therapeutics, Inc.